医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Nippon Soda and Syngenta Enter into Global Licensing Agreement for Novel Seed Treatment Technology

2018年02月26日 PM04:00
このエントリーをはてなブックマークに追加

Smart Multimedia Gallery

 

TOKYO & BASEL, Switzerland

Nippon Soda and Syngenta announced today a global seed treatment licensing agreement for PICARBUTRAZOX, a new active ingredient from a novel chemical class discovered by Nippon Soda. It shows robust and reliable performance for the control of Pythium damping off and seedling blight diseases under many different cropping systems.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180225005248/en/

Tackling Pythium allows farmers to adopt reduced or no-tillage cropping systems protecting the soil, avoid the costs of having to replant and get benefits from better germination, strong stand establishment and higher yields.

Ioana Tudor, Global Head of Syngenta Seedcare, said “We are proud that Nippon Soda has partnered with Syngenta Seedcare to bring this exciting technology to the seed industry and farmers globally. PICARBUTRAZOX, with its novel mode of action will strengthen Syngenta’s leading Pythium control portfolio Mefenoxam and Azoxystrobin Technology in corn, soybeans, canola, oilseed rape, cereals and other crops.”

Chinami Yokota, Nippon Soda Director of Development Department, said “Nippon Soda has strong research capabilities and it was an excellent decision to choose Syngenta Seedcare as a leader in the seed treatment market to broaden the use of PICARBUTRAZOX beyond foliar application.”

First registrations of PICARBUTRAZOX on seed treatment are expected in the United States and Canada in 2019.

About Syngenta

Syngenta is a leading agriculture company helping to improve global food security by enabling millions of farmers to make better use of available resources. Through world class science and innovative crop solutions, our 27,500 people in over 90 countries are working to transform how crops are grown. We are committed to rescuing land from degradation, enhancing biodiversity and revitalizing rural communities. To learn more visit www.syngenta.com and www.twitter.com/Syngenta.

Find out more about Syngenta Seedcare at https://www.syngentaseedcare.com/.

About Nippon Soda

Since our founding in 1920, Nippon Soda has accumulated unique technologies and know-how, and provided highly functional and high-value-added chemical products in such diverse fields as agriculture, pharmaceuticals and specialty chemicals. Furthermore, as a company that handles chemical substances, we have always been mindful of the doctrine of responsible care and have driven business activities with attention to the environment, safety and health. Going forward, Nippon Soda will contribute to the building of a rich society that realizes the dreams of the next generation through innovative technologies and products.

For additional information, visit the company’s website at www.nippon-soda.co.jp.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180225005248/en/

CONTACT

Syngenta International AG
Media Office
Telephone: +41
61 323 23 23
Fax: +41 61 323 24 24
www.syngenta.com
or
Syngenta
Media:

Switzerland
Andrew McConville, +41 61 323 0618
media.relations@syngenta.com
or
USA
Paul
Minehart, +1 202-737-8913
or
Syngenta Analyst/Investor:
Andrew
McConville
Switzerland: +41 61 323 0618
USA: +1 202-737-6521
or
Nippon
Soda Co., Ltd.

Stakeholder Relations Group
Telephone: +81
3 3245 6054
Fax: +81 3 3245 6238
www.nippon-soda.co.jp
or
Nippon
Soda Media:

Japan
Satoshi Takeuchi, +81 3 3245 6053
info@nippon-soda.co.jp

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表